Antineutrophil cytoplasmatic antibodies (ANCA) have been detected in patients with systemic lupus erythematosus (SLE). In this study, we investigated the presence of ANCA in a sample of Brazilian SLE patients and its possible associations with clinical and serological outcomes. Additionally, we reviewed the literature of on ANCA in SLE.
Results
The presence of ANCA was detected in 130 patients using indirect immunofluorescence (IIF). The test was positive in 29.9% of the cases (17.6% pANCA and 11.5% cANCA). Male sex and peripheral vasculitis were more prevalent in the ANCA-positive sample. cANCA was associated with lupus anticoagulant and pANCA had a positive association with peripheral vasculitis and a negative association with anti- SSB/La antibodies. In the 22 studies included in the literature review, a wide range of ANCA positivity was found (13% to 81.1% by IIF and 0 to 22.2% by ELISA). ANCA was associated with renal damage in the Asian population. Although other associations have been found in isolated studies, they were not consistently reported.
Conclusions
The ANCA prevalence found in this Brazilian sample was within the range reported in the literature and these autoantibodies were more frequent in males and in patients with vasculitis. The literature showed controversial results on the association between ANCA and SLE disease activity or clinical characteristics.
FolciMRamponiGSolitanoV, et al.Serum ANCA as disease biomarkers: clinical implications beyond vasculitis. Clin Rev Allergy Immunol2022; 63(2): 107–123. DOI: 10.1007/s12016-021-08887-w.
2.
LiCWangJJZhouML, et al.Differences in clinico-pathological characteristics and outcomes between proteinase 3-ANCA positivity and myeloperoxidase-ANCA positivity in lupus nephritis. Lupus2019; 28(9): 1111–1119. DOI: 10.1177/0961203319861680.
NahumYSagyICohenY, et al.The effect of different ethnic origins in Israel on the clinical manifestations and outcomes of systemic lupus erythematous. Isr Med Assoc J2023; 25(3): 221–226.
5.
TrivioliGMarquezAMartoranaD, et al.Genetics of ANCA-associated vasculitis: role in pathogenesis, classification and management. Nat Rev Rheumatol2022; 18(10): 559–574. DOI: 10.1038/s41584-022-00819-y.
6.
AringerMCostenbaderKDaikhD, et al.2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019; 71: 1400–1412. DOI: 10.1136/annrheumdis-2018-214819.
7.
BajemaIMWilhelmusSAlpersCE, et al.Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int2018; 93(4): 789–796. DOI: 10.1016/j.kint.2017.11.023.
8.
GladmanDGlinzlerEGoldsmithC, et al.The development and initial validation of the Systemic lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–378. DOI: 10.1002/art.1780390303.
9.
PetriMKimMYKalunianKC, et al.Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med2005; 353: 2550–2558. DOI: 10.1056/NEJMoa051135.
10.
MoherDLiberatiATetzlaffJPRISMA Group, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ2009; 339: b2535. DOI: 10.1186/s13643-020-01542-z.
11.
ChenMZhaoMHZhangYK, et al.Antineutrophil cytoplasmic autoantibodies in patients with systemic lupus erythematosus recognize a novel 69 kDa target antigen of neutrophil granules. Nephrology2005; 10(5): 491–495. DOI: 10.1111/j.1440-1797.2005.00441.x.
12.
PanHFFangXHWuGC, et al.Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation2008; 31(4): 260–265. DOI: 10.1007/s10753-008-9073-3.
13.
WangYHuangXCaiJ, et al.Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: a retrospective study. Medicine (Baltim)2016; 95(4): e2580. DOI: 10.1097/MD.0000000000002580.
14.
SuFXiaoWYangP, et al.Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus. An Bras Dermatol2017; 92(4): 466–469. DOI: 10.1590/abd1806-4841.20175476.
15.
LiCZhouMLLiangDD, et al.Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. BMJ Open2017; 7(7): e015668. DOI: 10.1136/bmjopen-2016-015668.
16.
WangSShangJXiaoJ, et al.Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody. Ren Fail2020; 42(1): 244–254. DOI: 10.1080/0886022X.2020.1735416.
17.
WangYYuXXieX, et al.Clinical features and outcomes of patients with antineutrophil cytoplasmic antibody-positive systemic lupus erythematosus. Ren Fail2023; 45(1): 2235431. DOI: 10.1080/0886022X.2023.2235431.
18.
ChinHJAhnCLimCS, et al.Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol2000; 20(1): 57–63. DOI: 10.1159/000013557.
19.
PyoJYJungSMSongJJ, et al.ANCA positivity at the time of renal biopsy is associated with chronicity index of lupus nephritis. Rheumatol Int2019; 39(5): 879–884. DOI: 10.1007/s00296-019-04263-2.
20.
SchnabelACsernokEIsenbergDA, et al.Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Prevalence, specificities, and clinical significance. Arthritis Rheum1995; 38(5): 633–637. DOI: 10.1002/art.1780380509.
21.
SpronkPEBootsmaHHorstG, et al.Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol1996; 35(7): 625–631. DOI: 10.1093/rheumatology/35.7.625.
22.
NishiyaKChikazawaHNishimuraS, et al.Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. Clin Rheumatol1997; 16(1): 70–75. DOI: 10.1007/BF02238766.
23.
MolnárKKovácsLKissM, et al.Anti-neutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus. Clin Exp Dermatol2002; 27(1): 59–61. DOI: 10.1046/j.0307-6938.2001.00964.x.
24.
FauziARKongNCChuaMK, et al.Antibodies in systemic lupus antineutrophil cytoplasmic erythematosus: prevalence, disease activity correlations and organ system associations. Med J Malaysia2004; 59(3): 372–377.
25.
OlsonSWLeeJJPoirierM, et al.Anti-myeloperoxidase antibodies associate with future proliferative lupus nephritis. Autoimmune Dis2017; 2017: 1872846. DOI: 10.1155/2017/1872846.
26.
Turner-StokesTWilsonHRMorrealeM, et al.Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int2017; 92(5): 1223–1231. DOI: 10.1016/j.kint.2017.04.029.
LaceteraRCalatroniMRoggeroL, et al.Prevalence and clinical significance of ANCA positivity in lupus nephritis: a case series of 116 patients and literature review. J Nephrol2023; 4: 1059–1070. DOI: 10.1007/s40620-023-01574-3.
29.
ManolovaIDanchevaMHalachevaK. Antineutrophil cytoplasmic antibodies in patients with systemic lupus erythematosus: prevalence, antigen specificity, and clinical associations. Rheumatol Int2001; 20(5): 197–204. DOI: 10.1007/s002960100108.
30.
GaleazziMMorozziGSebastianiGD, et al.Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol1998; 16(5): 541–546.
31.
NovoEVieraNNovoE. Antineutrophil cytoplasmic antibodies: a missing link in the pathogenesis of periodontal disease?J Periodontal Res1996; 31(5): 365–368. DOI: 10.1111/j.1600-0765.1996.tb00504.x.
32.
KobayashiTItoSYasudaK, et al.The combined genotypes of stimulatory and inhibitory Fc gamma receptors associated with systemic lupus erythematosus and periodontitis in Japanese adults. J Periodontol2007; 78(3): 467–474. DOI: 10.1902/jop.2007.060194.
33.
NovoEGarcía-Mac GregorENavaS, et al.A possible defective estimation of antineutrophil cytoplasmic antibodies in systemic lupus erythematosus due to the coexistence of periodontitis: preliminary observations. Puert Rico Health Sci J, 1997; 16(4): 369–373.
TamiyaHTaniKMiyataJ, et al.Defensins- and cathepsin G-ANCA in systemic lupus erythematosus. Rheumatol Int2006; 27(2): 147–152. DOI: 10.1007/s00296-006-0173-9.
36.
ArgyropoulouODGoulesAVBoutziosG, et al.Occurrence and antigenic specificity of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in systemic autoimmune diseases. Cells2021; 10(8): 2128. DOI: 10.3390/cells10082128.
37.
ZhaoMHLiuNZhangYK, et al.Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant1998; 13(11): 2821–2824. DOI: 10.1093/ndt/13.11.2821.
ZhangZJinLLiuL, et al.The intricate relationship between autoimmunity disease and neutrophils death patterns: a love-hate story. Apoptosis2023; 28(9-10): 1259–1284. DOI: 10.1007/s10495-023-01874-w.
40.
LockeICLeakerBCambridgeG. A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions. Clin Exp Immunol1999; 115(2): 369–376. DOI: 10.1046/j.1365-2249.1999.00809.x.
41.
HsiehSCYuHSLinWW, et al.Anti-SSB/La is one of the antineutrophil autoantibodies responsible for neutropenia and functional impairment of polymorphonuclear neutrophils in patients with systemic lupus erythematosus. Clin Exp Immunol2003; 131(3): 506–516. DOI: 10.1046/j.1365-2249.2003.02084.x.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
